Asset Details
Do you wish to reserve the book?
Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis
Do you wish to request the book?
Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis
2011
Overview
Elevated C-reactive protein (CRP) is a common finding in patients with aortic stenosis (AS) and may be associated with rapid AS progression and worse outcome. The purpose of the study was to examine the role of high-sensitivity CRP and its interaction with rosuvastatin on the progression of AS.
We measured CRP at baseline, 1 year, and end of follow-up in 260 patients with a median follow-up of 3.5 years. Analyses were performed based on baseline CRP tertiles and baseline CRP >3 and ≤3 mg/L.
After adjustment for baseline characteristics, higher CRP levels were associated with age, female gender, body mass index, and lower high-density lipoprotein cholesterol levels but not with AS severity. Treatment with rosuvastatin led to a persistent decrease in CRP at 1 year and end of follow-up. Progression of AS was detected in patients in all 3 CRP tertiles, and rosuvastatin treatment had no impact on progression in all 3 tertiles. Similar findings were observed using CRP >3 mg/L as the cutpoint. Multiple linear regression showed that baseline AS velocity (P < .001), but not CRP, was the only predictor of progression of AS; age (P = .05) and baseline AS velocity (P < .001), but not CRP and rosuvastatin treatment, were predictors of outcome events.
C-reactive protein does not predict severity, progression, and prognosis in patients with mild to moderate AS. Treatment with rosuvastatin reduces CRP levels but has no effect on the progression and clinical events of AS.
Publisher
Elsevier Inc,Mosby,Elsevier Limited
Subject
/ Age
/ Aged
/ Antigens
/ Aortic Valve Stenosis - blood
/ Aortic Valve Stenosis - pathology
/ Biological and medical sciences
/ C-Reactive Protein - analysis
/ C-Reactive Protein - drug effects
/ Endocardial and cardiac valvular diseases
/ Female
/ Fluorobenzenes - pharmacology
/ Heart
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
/ Lipids
/ Male
/ Proteins
